Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma
- PMID: 34339648
- DOI: 10.1016/S1470-2045(21)00378-8
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma
Conflict of interest statement
We declare no competing interests.
Comment in
-
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply.Lancet Oncol. 2021 Aug;22(8):e346. doi: 10.1016/S1470-2045(21)00418-6. Lancet Oncol. 2021. PMID: 34339649 No abstract available.
Comment on
-
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources